The instruction
for medical use
of PAPAVERINE medicine
the Trade name
the Papaverine
the International unlicensed name
Is not present
the Dosage form
of the Tablet of 0.04 g
Structure
One tablet
the hydrochloride of 0.040 g,
excipients contains active agent of a papaverine: potato starch, sucrose, stearic acid.
The description
of the Tablet of white color, ploskotsilindrichesky with risky and a facet.
Pharmacotherapeutic group
Drugs for treatment of functional disorders of a GIT. Papaverine and its derivatives.
The code of automatic telephone exchange A03AD01
the Pharmacological
Pharmacokinetics Later properties of intake is quickly absorbed in digestive tract. The bioavailability is 29-57%. Therapeutic effective concentration of drug in blood plasma make 0.2-2.0 mkg/ml. At repeated use of drug its pharmacokinetics does not change.
Contacts proteins of blood plasma for 90%. Easily passes through gistogematichesky barriers. In a liver and fatty tissue forms depot. Is exposed to biotransformation in a liver. The semi-elimination period (T½) a papaverine is 0.5-2.0 h. It is removed in the form of the phenolic metabolites conjugated with glucuronic acid with urine, insignificant quantities of a papaverine (less than 0.5%) are removed in not changed look.
The pharmacodynamics
the Papaverine has hypotensive and myotropic spasmolytic effect.
The mechanism of action is connected with ability of a papaverine to block activity of phosphodiesterase IV of type. Blockade of enzyme leads to the termination of hydrolysis of tsAMF and increase in its concentration in smooth muscle cells of vessels, internals. tsAMF limits receipt of calcium ions in a muscle cell and inactivates a kinase of light chains of myosin of sokratitelny protein which provides reduction of a muscle.
The papaverine reduces a tone and relaxes unstriated muscles of internals (digestive tract, airways, an urinogenital system) and vessels. The papaverine expands mainly arterial vessels and promotes increase in a blood-groove, including cerebral. Has hypotensive effect. In high doses reduces excitability of a cardiac muscle and slows down intracardial conductivity.
At use in average therapeutic doses the papaverine has practically no effect on the central nervous system.
Indications
- spasms of unstriated muscles of internals in cholecystitis, a spastic colitis, a pylorospasm (prevention and stopping)
- encephalopathies of vascular genesis (as a part of complex therapy)
Apply the Route of administration and doses inside on an empty stomach. The adult appoint for 0.04-0.06 (1-1½, tablets) 3-5 times a day. The highest single dose of 0.4 g (10 tablets), maximum daily dose of 0.60 g (15 tablets). Duration of a course of treatment is 10-14 days, if necessary carrying out repeated courses of use of drug at an interval of 7-10 days is possible.
At persons 70 years an initial single dose no more than 0.01 g are more senior (& frac14, tablets).
To children from 10 years appoint in a dose 0.3-0.5 mg/kg of weight 2-3 times a day.
Side effects
- nausea, constipations
- drowsiness
- the increased perspiration
- increase in level of transaminases, an eosinophilia
- hypotension, atrioventikulyarny blockade, ventricular premature ventricular contraction
of the Contraindication
- hypersensitivity to a papaverine and other components
of drug
- respiratory depression or coma
- atrioventikulyarny blockade
- glaucoma
- children's age up to 10 years
- age are more senior than 75 years (risk of a hyperthermia)
Medicinal interactions
Reduces protivoparkinsonichesky effect of a levodopa and hypotensive effect Methyldopums. In a combination with barbiturates the spasmolytic action of a papaverine of a hydrochloride amplifies. At combined use with tricyclic antidepressants, procaineamide, reserpine, quinidine sulfate strengthening of hypotensive effect is possible.
Special instructions
It is necessary to be careful and use only small doses of a papaverine at persons with a craniocereberal injury, abnormal liver functions and kidneys, a hypothyroidism, insufficiency of function of adrenal glands as they strengthen hypotensive action of a papaverine. At persons with a benign hyperplasia of a prostate the high doses of a papaverine can provoke development of a sharp ischuria.
During use of a papaverine of a hydrochloride it is necessary to exclude the use alcohol - the containing drinks and also the medicines containing alcohol.
Use in pediatrics
Use of tablets of a papaverine of a hydrochloride for children up to 10 years is not recommended.
Pregnancy and a lactation
At pregnancy and in the period of a lactation safety and efficiency of use of a papaverine of a hydrochloride are not established.
Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
Considering side effects of drug it is necessary to be careful at control of motor transport or other mechanisms.
Overdose
Symptoms: diplopia, weakness, drowsiness, hypotension.
Treatment: specific antidote does not exist. Measures of the help include drug withdrawal, gastric lavage with milk and activated carbon and the symptomatic therapy directed to elimination of the arisen disturbances and increase in arterial blood pressure.
A form of release and packing
On 10 tablets in blister strip packaging from a film of the polyvinylchloride and printing aluminum foil varnished.
On 10 tablets in planimetric bezjyacheykovy packing from paper with a polymeric covering or from the material combined on a paper and cardboard basis.
800 planimetric cell or 700 planimetric bezjyacheykovy packs with the equal number of instructions for medical use in the state and Russian languages place in group packing.
To Store storage conditions in the dry, protected from light place at
a temperature not over 25 of 0C
to Store out of children's reach!
Not to apply a period of storage of 5 years after an expiration date.
Prescription status
Without prescription
JSC Irbitsky Producer the chemical and pharmaceutical plant,
Russia 623856, Sverdlovsk Region, Irbit, Kirov St., 172 Ph. / fax (34355) 3-60-90
The owner of the registration certificate
of JSC Irbitsky the chemical and pharmaceutical plant, Russia
the Address of the organization accepting claims for territories of the Republic of Kazakhstan from consumers on quality of products:
JSC Irbitsky chemical and pharmaceutical plant,
Russia 623856, Sverdlovsk Region, Irbit, Kirov St., 172 Ph. / fax (34355) 3-60-90
E-mail address: info@ihfz.ru
for medical use
of PAPAVERINE medicine
the Trade name
the Papaverine
the International unlicensed name
Is not present
the Dosage form
of the Tablet of 0.04 g
Structure
One tablet
the hydrochloride of 0.040 g,
excipients contains active agent of a papaverine: potato starch, sucrose, stearic acid.
The description
of the Tablet of white color, ploskotsilindrichesky with risky and a facet.
Pharmacotherapeutic group
Drugs for treatment of functional disorders of a GIT. Papaverine and its derivatives.
The code of automatic telephone exchange A03AD01
the Pharmacological
Pharmacokinetics Later properties of intake is quickly absorbed in digestive tract. The bioavailability is 29-57%. Therapeutic effective concentration of drug in blood plasma make 0.2-2.0 mkg/ml. At repeated use of drug its pharmacokinetics does not change.
Contacts proteins of blood plasma for 90%. Easily passes through gistogematichesky barriers. In a liver and fatty tissue forms depot. Is exposed to biotransformation in a liver. The semi-elimination period (T½) a papaverine is 0.5-2.0 h. It is removed in the form of the phenolic metabolites conjugated with glucuronic acid with urine, insignificant quantities of a papaverine (less than 0.5%) are removed in not changed look.
The pharmacodynamics
the Papaverine has hypotensive and myotropic spasmolytic effect.
The mechanism of action is connected with ability of a papaverine to block activity of phosphodiesterase IV of type. Blockade of enzyme leads to the termination of hydrolysis of tsAMF and increase in its concentration in smooth muscle cells of vessels, internals. tsAMF limits receipt of calcium ions in a muscle cell and inactivates a kinase of light chains of myosin of sokratitelny protein which provides reduction of a muscle.
The papaverine reduces a tone and relaxes unstriated muscles of internals (digestive tract, airways, an urinogenital system) and vessels. The papaverine expands mainly arterial vessels and promotes increase in a blood-groove, including cerebral. Has hypotensive effect. In high doses reduces excitability of a cardiac muscle and slows down intracardial conductivity.
At use in average therapeutic doses the papaverine has practically no effect on the central nervous system.
Indications
- spasms of unstriated muscles of internals in cholecystitis, a spastic colitis, a pylorospasm (prevention and stopping)
- encephalopathies of vascular genesis (as a part of complex therapy)
Apply the Route of administration and doses inside on an empty stomach. The adult appoint for 0.04-0.06 (1-1½, tablets) 3-5 times a day. The highest single dose of 0.4 g (10 tablets), maximum daily dose of 0.60 g (15 tablets). Duration of a course of treatment is 10-14 days, if necessary carrying out repeated courses of use of drug at an interval of 7-10 days is possible.
At persons 70 years an initial single dose no more than 0.01 g are more senior (& frac14, tablets).
To children from 10 years appoint in a dose 0.3-0.5 mg/kg of weight 2-3 times a day.
Side effects
- nausea, constipations
- drowsiness
- the increased perspiration
- increase in level of transaminases, an eosinophilia
- hypotension, atrioventikulyarny blockade, ventricular premature ventricular contraction
of the Contraindication
- hypersensitivity to a papaverine and other components
of drug
- respiratory depression or coma
- atrioventikulyarny blockade
- glaucoma
- children's age up to 10 years
- age are more senior than 75 years (risk of a hyperthermia)
Medicinal interactions
Reduces protivoparkinsonichesky effect of a levodopa and hypotensive effect Methyldopums. In a combination with barbiturates the spasmolytic action of a papaverine of a hydrochloride amplifies. At combined use with tricyclic antidepressants, procaineamide, reserpine, quinidine sulfate strengthening of hypotensive effect is possible.
Special instructions
It is necessary to be careful and use only small doses of a papaverine at persons with a craniocereberal injury, abnormal liver functions and kidneys, a hypothyroidism, insufficiency of function of adrenal glands as they strengthen hypotensive action of a papaverine. At persons with a benign hyperplasia of a prostate the high doses of a papaverine can provoke development of a sharp ischuria.
During use of a papaverine of a hydrochloride it is necessary to exclude the use alcohol - the containing drinks and also the medicines containing alcohol.
Use in pediatrics
Use of tablets of a papaverine of a hydrochloride for children up to 10 years is not recommended.
Pregnancy and a lactation
At pregnancy and in the period of a lactation safety and efficiency of use of a papaverine of a hydrochloride are not established.
Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
Considering side effects of drug it is necessary to be careful at control of motor transport or other mechanisms.
Overdose
Symptoms: diplopia, weakness, drowsiness, hypotension.
Treatment: specific antidote does not exist. Measures of the help include drug withdrawal, gastric lavage with milk and activated carbon and the symptomatic therapy directed to elimination of the arisen disturbances and increase in arterial blood pressure.
A form of release and packing
On 10 tablets in blister strip packaging from a film of the polyvinylchloride and printing aluminum foil varnished.
On 10 tablets in planimetric bezjyacheykovy packing from paper with a polymeric covering or from the material combined on a paper and cardboard basis.
800 planimetric cell or 700 planimetric bezjyacheykovy packs with the equal number of instructions for medical use in the state and Russian languages place in group packing.
To Store storage conditions in the dry, protected from light place at
a temperature not over 25 of 0C
to Store out of children's reach!
Not to apply a period of storage of 5 years after an expiration date.
Prescription status
Without prescription
JSC Irbitsky Producer the chemical and pharmaceutical plant,
Russia 623856, Sverdlovsk Region, Irbit, Kirov St., 172 Ph. / fax (34355) 3-60-90
The owner of the registration certificate
of JSC Irbitsky the chemical and pharmaceutical plant, Russia
the Address of the organization accepting claims for territories of the Republic of Kazakhstan from consumers on quality of products:
JSC Irbitsky chemical and pharmaceutical plant,
Russia 623856, Sverdlovsk Region, Irbit, Kirov St., 172 Ph. / fax (34355) 3-60-90
E-mail address: info@ihfz.ru
Related Products
-21%
